Dianthus Therapeutics 320% Year: What Investors Should Know as Stakes Shift
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
This page covers the main factors that move indices, including earnings, policy, and macro conditions, with tips for interpreting changes.
28,658 articlesDianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
CoreWeave has fallen roughly 40% over the past year even as peers rally, highlighting a split in the AI infrastructur...
A former State Department Official breaks down who benefits from geopolitical tensions and how to shield your wallet ...
A top move in growth investing is drawing attention: cathie wood's invest bought SpaceX stock. This article breaks do...
NVIDIA's leadership and AI-driven demand are reshaping the stock market landscape. This article dives into what Jense...
IBM's shares sank as Anthropic's Claude Code intensifies AI competition, pushing ibm’s stock heads worst for a month ...
Rocket Lab faces a watershed moment as it logs another quarter of rising revenue and a multi-billion backlog while we...
Meta Platforms appears poised for a potential move toward $700 as earnings beat and AI-driven monetization clash with...
A 17% drop in NUGT on Friday highlights the peril of 2x leverage in mining ETFs as gold prices retreat and larger min...
Pulmonx is navigating a pivotal year as it advances its lung care devices while contending with pacing competition an...
Greg Abel, stepping into Warren Buffett's shadow, has quietly tripled Berkshire's Alphabet stake. Is this the kind of...
Smart, patient investors are weighing Ford in a way that goes beyond the headline numbers. Here are two durable reaso...